Omalizumab can be considered a first-line treatment in patients with early-onset allergic asthma with a history of allergies and/or clinically significant IgE >100 IU/mL with allergic rhinitis and moderately elevated fractional exhaled nitric oxide (FeNO) (50 ppd) (Eyerich et al., 2020). Here, IGHE is linked to allergic asthma.